The dilemma to select appropriate excipients for paediatric products can be resolved by applying systematic benefit-risk assessment process, by using the newly developed “Paediatric Excipient Risk Assessment (PERA)” framework and tool which will be presented and demonstrated by case studies in this session. Attendees will gain insights into how to balance functionality with safety to support the development of effective pediatric patient centric medicines.
